Tandem Diabetes Care, Inc. has agreed to pay $36 million to Roche to settle a patent infringement lawsuit involving its t:slim X2 insulin pump.
The agreement resolves all current and potential legal disputes over two European patents—EP 2 196 231 B1 and EP 1 970 677 B1—that Roche filed in December 2023. Tandem will make an upfront payment of $8 million, followed by four annual payments of $7 million over the next four years.
As part of the deal, both companies have signed a ten-year cross-license agreement. This agreement allows each company to use certain insulin delivery system patents held by the other, on a non-exclusive, non-sublicensable, royalty-free, and irrevocable basis.
The settlement brings an end to all ongoing litigation under the Unified Patent Court in France and Germany. This includes lawsuits related to patent infringement, revocation, and non-infringement.
Thanks to the agreement, Tandem’s t:slim X2 insulin pump will remain available on the market. The settlement also reduces future legal risks for both companies.
Related Topics:
